small molecule

ABILIFY MAINTENA KIT

ARIPIPRAZOLE

Loss of exclusivityApril 2034latest FDA-listed patent expiry
CompanyOtsuka PharmaceuticalView the full company profile on CliffBio

Drug detail

Brand nameABILIFY MAINTENA KIT
Active ingredientARIPIPRAZOLE
Strength300MG/VIAL
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalFebruary 2013
Marketing statusRX

Listed patents

PatentExpiresType
11648347April 2034product
10525057March 2034use U-2723
11344547September 2033use U-814
11400087September 2033use U-1632
10980803September 2033use U-1632
11154553September 2033use U-3245

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ABILIFY MAINTENA KIT patent cliff — loss of exclusivity April 2034 | CliffBio